Comparing Filgrastim vs Promacta
| Filgrastim | Promacta (eltrombopag) |
|
|---|
| Filgrastim | Promacta (eltrombopag) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Neutropenia Associated with Chemotherapy, Neutropenia, Aplastic Anemia, Bone Marrow Transplantation, Hematopoietic Syndrome of Acute Radiation Syndrome, Neutropenia Associated with... View more |
Prescription only
Promacta is an oral tablet or suspension that is taken daily to boost platelet numbers in people with chronic ITP, severe aplastic anemia, or chronic hepatitis C. Nausea, diarrhea, infections, and... View more |
Related suggestions Aplastic Anemia
Popular comparisons
|
|||||||
| More about Filgrastim | More about Promacta (eltrombopag) | ||||||||
| Ratings & Reviews | |||||||||
|
Filgrastim has an average rating of 8.0 out of 10 from a total of 10 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 20% reported a negative effect. |
Promacta has an average rating of 6.8 out of 10 from a total of 18 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 22% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Filgrastim side effects |
View all Promacta side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Promacta prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Neupogen, Nivestym, Nypozi, Releuko, Zarxio | Other eltrombopag brands include: Alvaiz, Promacta Kit | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
5.8 hours |
35 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 175 drugs are known to interact with Filgrastim:
|
A total of 186 drugs are known to interact with Promacta:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
November 20, 2008 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Udenyca
Udenyca is used for febrile neutropenia, hematopoietic syndrome of acute radiation syndrome ...
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Releuko
Releuko is used for bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.